Modified release
The demand for modified release formulations is driven by many factors related to both patient and therapeutic need. For most conditions, patients generally demand either once or twice daily treatments requiring sustained drug concentrations throughout the treatment period. Modified release formulations are designed to deliver your drug over a defined period of time and/or to a particular region of the body. By doing this, drug delivery can be optimized to balance therapeutic need, manage AE profiles and reduce dosing frequency, which contribute to improved patient compliance.
Quotient Sciences has extensive experience in designing modified release formulations, from gastro-retention to sustained and pulsatile release formats as outlined below.
| Modified release format | Objective | Formulation technology |
| Gastro-retention |
|
Swellable tablets (monolithic, bilayer, trilayer) |
| Gastric bypass |
|
Enteric coated tablets or capsules |
| Sustained or extended release |
|
Matrix tablets, coated tablets or multiparticulates |
| Targeted or controlled delivery |
|
Tablets, capsules or multiparticulates |
| Biphasic release |
|
Bilayer tablets or multiparticulates |
| Pulsatile release |
|
Bilayer tablets or multiparticulates |
Learn more about Modified Release formulation development
-
WhitepaperAlternative Strategies for Development of Modified Release Dosage FormsModified-release (MR) formulations are in high demand. For formulators, they enable drugs to be released in the optimal gastrointestinal (GI) locations to achieve and maintain desirable plasma concentrations for extended periods, avoiding undesirable excursions outside the therapeutic range.
-
Info SheetTranslational PharmaceuticsQuotient Sciences helps you achieve your goals by enabling precise formulation development, streamlined manufacturing, quick pivot to clinical data and a significantly faster transition through drug development.
-
Info SheetGlobal Formulation Development and Manufacturing CapabilitiesWe provide full service support for small molecule non-sterile programs, from dosage formulation development through to GMP clinical trial manufacturing and commercial drug product supply.
-
Info SheetFormulation DevelopmentFrom preclinical and first-in-human (FIH) dosage forms to optimization of your drug products for late stage development, we work with you to develop the most appropriate formulation.